Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 1,866 shares of the business's stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $93.97, for a total value of $175,348.02. Following the completion of the sale, the chief financial officer now directly owns 67,542 shares in the company, valued at $6,346,921.74. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Michael Burkes Brophy also recently made the following trade(s):
- On Monday, April 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $93.14, for a total value of $115,307.32.
- On Thursday, April 25th, Michael Burkes Brophy sold 705 shares of Natera stock. The stock was sold at an average price of $89.55, for a total value of $63,132.75.
- On Tuesday, April 23rd, Michael Burkes Brophy sold 1,523 shares of Natera stock. The stock was sold at an average price of $91.38, for a total value of $139,171.74.
- On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The shares were sold at an average price of $92.62, for a total transaction of $127,630.36.
- On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The stock was sold at an average price of $90.42, for a total transaction of $82,643.88.
- On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The shares were sold at an average price of $88.36, for a total transaction of $249,705.36.
- On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The stock was sold at an average price of $70.03, for a total transaction of $2,383,050.87.
Natera Trading Up 3.5 %
Elon to Transform U.S. Economy?
From Porter & Company | Ad
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites.
And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
One company holds a near-total monopoly on it.
Shares of NTRA stock opened at $96.98 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. The company has a market cap of $11.71 billion, a price-to-earnings ratio of -25.59 and a beta of 1.38. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $98.82. The firm has a fifty day moving average price of $90.56 and a 200-day moving average price of $69.29.
Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.09. The company had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. As a group, equities analysts predict that Natera, Inc. will post -2.35 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Natera by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company's stock valued at $687,280,000 after purchasing an additional 588,147 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Natera by 0.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 7,556,792 shares of the medical research company's stock worth $334,388,000 after buying an additional 67,102 shares during the period. Kynam Capital Management LP boosted its holdings in Natera by 3.6% in the 3rd quarter. Kynam Capital Management LP now owns 3,003,668 shares of the medical research company's stock worth $132,912,000 after buying an additional 103,668 shares during the period. RTW Investments LP increased its stake in Natera by 1.5% in the 3rd quarter. RTW Investments LP now owns 2,651,783 shares of the medical research company's stock worth $117,341,000 after buying an additional 40,000 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Natera by 52.0% during the third quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company's stock valued at $111,930,000 after acquiring an additional 865,404 shares during the period. 99.90% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of research firms have commented on NTRA. StockNews.com raised Natera from a "sell" rating to a "hold" rating in a report on Wednesday. Craig Hallum initiated coverage on Natera in a report on Monday, April 8th. They issued a "buy" rating and a $117.00 price objective for the company. Canaccord Genuity Group upped their target price on shares of Natera from $87.00 to $100.00 and gave the company a "buy" rating in a research note on Thursday, February 29th. Sanford C. Bernstein raised shares of Natera from a "market perform" rating to an "outperform" rating and set a $120.00 price target on the stock in a report on Friday, April 5th. Finally, The Goldman Sachs Group boosted their price objective on shares of Natera from $90.00 to $100.00 and gave the company a "buy" rating in a report on Monday, April 15th. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $86.40.
View Our Latest Stock Analysis on NTRA
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
